B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28 families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition of T-cell function. Importantly, B7-H3 is highly overexpressed on a wide range of human solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Challenges remain to identify the receptor(s) of B7-H3 and thus better elucidate the role of the B7-H3 pathway in immune responses and tumor evasion. With a preferential expression on tumor cells, B7-H3 is an attractive target for cancer immunotherapy. Based on the clinical success of inhibitory immune checkpoint blockade (CTLA-4, PD-1, and PD-L1), mAbs against B7-H3 appear to be a promising therapeutic strategy worthy of development. An unconventional mAb against B7-H3 with antibody-dependent cell-mediated cytotoxicity is currently being evaluated in a phase I clinical trial and has shown encouraging preliminary results. Additional therapeutic approaches in targeting B7-H3, such as blocking mAbs, bispecific mAbs, chimeric antigen receptor T cells, small-molecule inhibitors, and combination therapies, should be evaluated, as these technologies have already shown positive results in various cancer settings. A better understanding of the B7-H3 pathway in humans will surely help to further optimize associated cancer immunotherapies.
Background
During an immune response, na€ ve T cells engage their T-cell receptor (TCR) to interact with a complex of MHC and peptide expressed by antigen-presenting cells (APC). This first signal is not sufficient to trigger full T-cell activation. A second signal is provided by the interaction of costimulatory molecules (most importantly B7-1/2 and CD28), leading to full T-cell activation. Following activation, coinhibitory molecules, such as CTL-associated protein 4 (CTLA-4), function to restrain T-cell responses, resulting in T-cell exhaustion and tolerance. Interactions between members of the B7 ligand family and the CD28 receptor family provide T-cell costimulation and coinhibition, regulating T-cell activation and tolerance, exhaustion and effector function, differentiation, and memory generation. B7-H3, also known as CD276, is an immune checkpoint molecule belonging to the B7-CD28 pathways.
Structure and functional significance of the B7-H3 pathway B7-H3 is a type I transmembrane protein encoded by chromosome 9 in mice and 15 in humans. The extracellular domain is composed of a single pair of immunoglobulin variable domain and immunoglobulin constant domain in mice (2IgB7-H3 isoform) and two identical pairs in human (4IgB7-H3 isoform) due to exon duplication (1, 2) . The intracellular tail of B7-H3 is short and has no known signaling motif. B7-H3 was first described in humans (3) and then in mice (2) but is universally expressed among species (4) . A soluble form, cleaved from the surface by a matrix metallopeptidase (MMP; ref. 5) or produced through alternative splicing of the intron (6) , is also detectable in human sera.
B7-H3 is expressed on many tissues and cell types. At the mRNA level, it is ubiquitously found in such nonlymphoid and lymphoid organs as the liver, heart, prostate, spleen, and thymus. Despite broad mRNA expression, protein expression is limited at steady state, suggesting the presence of an important posttranscriptional control mechanism. B7-H3 is constitutively found on nonimmune resting fibroblasts, endothelial cells (EC), osteoblasts, and amniotic fluid stem cells. Moreover, B7-H3 expression is induced on immune cells, specifically APCs. In particular, coculture with regulatory T cells (7) , IFNg, lipopolysaccharide (LPS), or anti-CD40 in vitro stimulation (8) all induce the expression of B7-H3 on dendritic cells (DC). Monocytes and monocytederived DCs upregulate B7-H3 after LPS stimulation or cytokineinduced differentiation, respectively (9) . In addition, B7-H3 is also detected on natural killer (NK) cells, B cells, and a minor population of T cells following PMA/ionomycin stimulation (1).
The B7-H3 pathway has a dual role in contributing to the regulation of innate immune responses. One study found that neuroblastoma cells express B7-H3 on their cell surface, which protect them from NK cell-mediated lysis (10) . Another group argues that B7-H3 costimulates innate immunity by augmenting proinflammatory cytokines release from LPS-stimulated monocytes/macrophages, in both a Toll-like receptor 4-and 2-dependent manner (11) . The role of B7-H3 in controlling the innate immunity is clearly complex and requires more elucidation.
A larger body of literature suggests that B7-H3 plays an important role in T cell-mediated adaptive immunity, although the nature of its signalling remains controversial (12) . A costimulatory role of B7-H3 on human T cells was initially reported in vitro (3). Murine studies showing B7-H3 worsens experimental autoimmune encephalomyelitis (EAE), arthritis, bacterial meningitis, and chronic allograft rejection (13) (14) (15) supported this claim. However, subsequent studies have mostly shown that B7-H3 acts as a T-cell coinhibitor. B7-H3 inhibits polyclonal or allogeneic CD4 and CD8 T-cell activation, proliferation, and effector cytokine production (IFNg and IL2) in mice and humans. This negative regulation of T cells is associated with diminished NFAT, NF-kB, and AP-1 transcriptional factor activity (16) . Researchers from independent studies using either protein blockade or gene-knockout mice have reported that B7-H3 ameliorates graft-versus-host disease, prolongs cardiac allograft survival, reduces airway hypersensitivity, and delays EAE onset, especially by downregulating Th1 responses (8, 17, 18) . These examples lend more credence to the coinhibitory nature of B7-H3.
The receptor(s) for B7-H3 has yet to be discovered (19, 20) . Nevertheless, the crystal structure of mouse B7-H3 reveals that its receptor engagement on T cells involves the particular segment connecting F and G strands (the FG loop) of the immunoglobulin variable domain of B7-H3 (19) . Moreover, B7-H3 crystallizes as a glycosylated monomer but also undergoes an unusual dimerization in vitro. Together, the nature of the receptor(s), differences in cellular context, and various disease models certainly account for the discrepancies in the function of the B7-H3 pathway in regulating both innate and adaptive immunity during homeostasis and inflammation.
Beyond the immune system, the B7-H3 pathway has a nonimmunologic role in promoting osteoblastic differentiation and bone mineralization in mice, ensuring normal bone formation (21) . Indeed, B7-H3 knockout mice had reduced bone mineral density and were more susceptible to bone fractures compared with wild-type mice. Furthermore, similar to other immune checkpoints of the B7-CD28 pathways, B7-H3 is also expressed in human cancers and participates in tumorigenesis through modulation of both immune and non-immune-related pathways.
B7-H3 in the tumor microenvironment and immune evasion
Numerous studies have described B7-H3 overexpression in human malignancies, including melanoma (22) , leukemia (23) , breast cancer (24) , prostate cancer (25) , ovarian cancer (26) , pancreatic cancer (27) , colorectal cancer (28) , and other cancers. As detected by immunochemistry technique, more than 60% and up to 93% of patient tumor tissues display aberrant expression of B7-H3 in the vast majority of cancer types (Table 1) , while limited expression is seen on normal healthy tissues. Within positively stained samples, B7-H3 is found on the membrane, in the cytoplasm, or within the nucleus of cancer cells but also on the tumor-associated vasculature. In a study of more than 700 colorectal cancer patients, cytoplasmic/membrane and stromal expression were respectively seen in 86% and 77% of the samples, whereas nuclear expression of B7-H3 in cancer cells was present in 27% of the samples (29) . In most studies, the intensity of the B7-H3 staining was further quantified and ranged from low to high expression. Finally, association studies investigated potential clinical correlation between tumor-associated B7-H3 and disease severity. Various clinicopathologic parameters were assessed, including tumor size, metastasis, cancer stage, survival, and recurrence rate. In most cases, a high expression of B7-H3 was correlated with bad prognosis and poor clinical outcome. One study with more than 800 prostate cancer patients revealed that patients with strong B7-H3 expression on tumor cells had a significantly increased risk of disease spread at the time of surgery, clinical cancer recurrence, and cancer-specific death (25) . B7-H3 expression in lung cancer was associated with a lower number of tumor-infiltrating lymphocytes and with lymph node metastasis, suggesting a role for B7-H3 in immune evasion and tumorigenesis (30) . Importantly, B7-H3 protein expression in tumors is known to be modulated by miR-29 (31), upregulated upon IFNg stimulation (32) , and potentially increased by immunoglobulin-like transcript 4 signaling (33) .
To date, the molecular mechanisms by which B7-H3 participates in tumor growth and immune evasion still remain elusive and need further investigation. Interestingly, aberrant glycosylation of B7-H3 was described in oral cancer. Its glycans, more diverse and with higher fucosylation, seem to interact better with DC-SIGN [DC-specific intercellular adhesion molecule-3 (ICAM-3)-grabbing nonintegrin] and Langerin (34) , proteins expressed on the membrane of DCs, suggesting a possible engagement and tolerization of DCs. Moreover, the cross-talk between lung cancer cells and tumor-associated macrophages, partially through IL10, induces B7-H3 membrane expression and inhibits T-cell antitumor immunity in mice (35) . Besides its role in modulating tumor immunity, B7-H3 also has a nonimmunologic function in regulating tumor aggressiveness. It was shown to modulate migration, invasion, and adhesion to fibronectin of various cancer cells (36) through the Jak2/Stat3/MMP-9 signaling pathway (37) . In addition, overexpression of B7-H3 in colorectal and breast cancer cells augments resistance to apoptosis by activating the Jak2/STAT3/ survivin signaling pathway. This, in turn, weakens tumor cell sensitivity to the chemotherapeutic drug paclitaxel (38, 39) . Furthermore, B7-H3 was shown to modulate the metastasisassociated proteins MMP-2, TIMP-1, TIMP-2, STAT3, and IL8 in melanoma cells (40) . In hepatoma cells, B7-H3 targeted the epithelial-to-mesenchymal transition via the Jak2/STAT3/Slug signaling pathway (41) . Finally, a recent study showed that decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors, unveiling a previously unknown link between B7-H3 and metabolism (42) . Together, these mechanisms promote aggression and invasion of the tumor.
Clinical-Translational Advances
The precise role of B7-H3 in regulating the function of tumorinfiltrating immune cells and its activity in cancer cells has yet to be fully elucidated. This absence is due in large part to the conflicting studies that have demonstrated B7-H3 to be either costimulatory or coinhibitory in several disease models. In addition, the receptor(s) that interact with B7-H3 have yet to be identified, magnifying the scrutiny. However, there is no doubt that aberrant expression of B7-H3 consists of a possible biomarker and a promising immune checkpoint target for multiple cancer immunotherapy approaches (Fig. 1) , as anticipated almost 10 years ago (43) . The scientific community is beginning to explore its therapeutic role in cancer in a variety of ways.
Blocking mAbs
The B7 ligand and CD28 receptor families have become attractive targets for cancer immunotherapy, with specific emphasis placed on the development of mAb blocking B7-CD28 pathways. Blocking mAbs against the immune checkpoints CTLA-4, programmed cell death protein 1 (PD-1), and PD-1 ligand 1 (PD-L1) have shown significant clinical success in patients with a variety of cancers (44) (45) (46) . This same logic and success can be extended to B7-H3 as well (Fig. 1A) . Blocking mAbs are effective because they either partially or completely neutralize inhibitory ligand-to-receptor interactions, thus allowing effector functions. Despite the fact that the B7-H3 binding partner(s) remains unknown and that mAbs generated against B7-H3 are specific to the protein, the ability of these mAbs to neutralize B7-H3 interactions and the signaling pathway remains unknown. Thus, currently, no blocking mAb against B7-H3 is available. Until this receptor (or receptors) is found, additional strategies in screening antibodies for neutralization capacity need to be developed.
Targeting B7-H3 through antibody-dependent cell-mediated cytotoxicity and antibody-drug conjugate therapies
The difficulties that have been encountered in creating blocking mAbs against B7-H3 have led to the optimization of antibodies against B7-H3 for therapy through alternative means (Fig. 1B) . Enoblituzumab (MGA271), a mAb reactive to cancer-associated B7-H3 showed enhanced antitumor function through potent antibody-dependent cell-mediated cytotoxicity (ADCC) against a broad range of tumor cell types. In mice, weekly doses of MGA271 in both renal and bladder carcinoma xenografts resulted in sustained tumor growth inhibition, effects that were Fc mediated (47) . Currently, an ongoing phase I study of enoblituzumab is being conducted in patients with refractory B7-H3-expressing tumors or B7-H3-expressing vasculature (trial NCT01391143). Preliminary results of the dose-escalation study indicate that as a monotherapy, the Fc-enhanced mAb enoblituzumab shows antitumor activity in several tumor types and modulates T cells by increasing the T-cell repertoire clonality in the peripheral blood of patients following treatment (48) . Although enoblituzumab is not a blocking mAb and its success largely depends on ADCC, the results are encouraging and open the door for more clinical trials targeting this protein by way of mAbs.
Alternatively, mAbs can be stably conjugated to a biologically active cytotoxic drug or compound that induces cell death. Once the mAb binds the cell-surface antigen, the complex is internalized, releasing the cytotoxic substance and killing cancer cells. 8H9 is a mAb specific to B7-H3 that showed clinical success as an antibody-drug conjugate (ADC) after it was radiolabeled to iodine-131 ( 131 I) and administrated to patients with metastatic central nervous system (CNS) neuroblastoma (49) . 8H9 also distinguishes itself from other B7-H3-specific antibodies in that it binds to the FG loop of B7-H3, a region critical to its immunologic function (50) . Recently, 8H9 was humanized and affinity matured and maintained its ability to kill B7-H3-positive neuroblastoma cells in vitro. Two-fold and 5-fold enhancements in killing were observed in the affinity-matured and humanized 8H9 compared with the nonmatured and chimeric generations, respectively. Furthermore, the mAb was labeled with 131 I and injected into athymic nude mice xenografted with human neuroblastoma and showed successful biodistribution to the tumor (50) . Currently, clinical trials with radiolabeled 8H9 are ongoing in patients with peritoneal cancers, gliomas, and advanced CNS cancers (NCT01099644, NCT01502917, and NCT00089245).
Bispecific antibodies
Bispecific antibodies are another suitable option beginning to pick up steam in the area of tumor immunotherapy. Bispecific antibodies are artificially generated antibodies composed of fragments of two distinct mAbs, thus combining two specificities. One arm can bind to the CD3 component of the TCR complex on T cells, while the other arm recognizes a tumor-specific antigen, for instance B7-H3, overexpressed on cancer cells (Fig. 1C) . That way, T cells are recruited to the tumor site and activated to kill cancer cells (51) . Given the upregulated expression of B7-H3 on multiple cancers, it seems like a promising option that should be pursued. Side effects of bispecific antibody treatment include an excessive inflammatory reaction due to cytokines produced by overactivated T cells but can be limited by corticosteroid administration. Targeting B7-H3 with small-molecule inhibitors With no current information known about the receptor(s) of B7-H3, the only viable target for disruption of this pathway is tumor-expressed B7-H3. In addition to conventional therapeutic mAbs, the roles of small-molecule inhibitors have also begun to gain interest in the immune-oncology field (52). Small-molecule inhibitors are low-molecular-weight organic compounds (dinucleotides, peptides, monosaccharides, etc.) that bind specific biological targets. They are readily used because of the advantages they offer in cheaper manufacturing costs, ease of delivery due to oral administration, greater tissue distribution due to size, and shorter half-life when compared with antibodies. Knowing that the receptor(s) of B7-H3 on activated T cells engages the FG loop of the IgV domain of B7-H3 (19), a small-molecule inhibitor could be designed to disturb this specific ligation area (Fig. 1D) . Although often unpredictable, off-target effects can arise and should be assessed as thoroughly as possible to limit detrimental consequences.
Targeting B7-H3 with chimeric antigen receptor T cells
Another interesting way to target B7-H3 for immunotherapy is with chimeric antigen receptor (CAR) T-cell technology (Fig. 1E ). This therapy recently had outstanding results in treating human refractive acute lymphoblastic leukemia (53, 54) . Autologous T cells are engineered with a CAR targeting a tumor antigen and adoptively transferred to patients to kill cancer cells. So far, this technology has been successfully applied to hematologic cancers only. Although this area of research is challenging, efforts are being made to translate CAR T-cell therapy to the treatment of solid tumors. Importantly, the target must be highly overexpressed by the tumor and low or absent in normal peripheral tissues, as B7-H3, to avoid off-tumor effects. Engineered T cells would have to reach the tumor site and penetrate the stroma to specifically kill the targeted tumor cells. Moreover, CAR T cells would be exposed to the immunosuppressive tumor microenvironment, which could alter their function. Some optimizations of CAR T cells are currently being made and will hopefully help, either alone or in a combination therapy, to treat solid cancers (55) . One clinical trial has evaluated the safety and antitumor activity of CAR T cells in patients with chemotherapy-refractory metastatic pancreatic cancer, with preliminary evidence of good tolerance and antitumor efficacy (56) . Of note, a cytokine release syndrome has been described in some patients and must be addressed to fully ensure the safety of this technique.
Synergistic options with anti-B7-H3 therapy: Chemotherapy or targeted therapy, immune checkpoint inhibitors, and radiation
The clinical successes of mAbs blocking immune checkpoints, such as CTLA-4, PD-1, and PD-L1, have led to the rationale of combining these modalities with conventional therapeutics or additional checkpoint inhibitors, with the goal of synergizing their actions and improving patient survival. The most traditional therapeutic regimen for treating cancers has been with chemotherapy. Recent studies have shown that the combination of a variety of chemotherapeutics with checkpoint inhibitors displays great synergistic effects that enhanced the prospects of its full utilization in standard clinical practice. The combination of an anti-CTLA-4 mAb (ipilimumab) and the chemotherapeutic drug dacarbazine, when compared with dacarbazine plus placebo, led to improved overall survival in patients with metastatic melanoma (57) . On the basis of a few preclinical animal studies, the combination of B7-H3 blockade and chemotherapy looks promising (Fig. 1F) . Indeed, the silencing of B7-H3 through shRNA in an histiocytic lymphoma-derived human cell line, U937, in combination with the antineoplastic drug Ara-C, led to 80% tumor reduction compared with the 40% inhibition observed in wild-type U937 cells combined with Ara-C in a mouse xenograft model (58) . Similarly, shRNA silencing of B7-H3 in a murine model of breast cancer, combined with the chemotherapeutic paclitaxel, led to an approximately 80% reduction in tumor growth compared with the untreated wild-type cells (38) . In both studies, silencing B7-H3 significantly enhanced tumor cell chemosensitivity and drug-induced apoptosis. Moreover, exploiting the differences between normal cells and cancer cells through targeted therapy as opposed to conventional chemotherapy may also deliver exciting results as a combination strategy. Taken together, these studies provide a rationale for the potential synergistic effects between B7-H3 blockade and chemotherapy or targeted therapy for patients with a variety of cancers.
The combination of multiple immune checkpoint inhibitors as a means for treating cancers has also been emerging quite rapidly. A recent study has shown that the combination of anti-PD-1 mAb (nivolumab) and ipilimumab in patients with previously untreated melanoma resulted in significantly longer progression-free survival than ipilimumab alone (59) . Furthermore, the combination of PD-1 and CTLA-4 blockade was able to demonstrate efficacy in patients with PD-L1-negative tumors compared with either agent alone. The expression pattern of B7-H3 contrasts greatly with that of the other checkpoint inhibitors in that the majority of B7-H3 can be found on tumor and tumor-associated tissue, while the others are expressed on immune cells, normal tissue, and cancerous cells. This difference in expression can be highly advantageous for generating not only local responses through the tumorspecific targeting of B7-H3, but also systemic activation of immune cells through additional checkpoint blockade, altogether potentially further enhancing antitumor immunity (Fig. 1F) . Despite the fact that no studies are available yet in preclinical models, phase I clinical trials are under way to explore the safety of enoblituzumab in combination with either ipilimumab or anti-PD-1 (pembrolizumab) in patients with refractory cancer (NCT02381314 and NCT02475213).
Radiation is an additional avenue that can be looked at in combination with B7-H3 targeting in a future clinical setting (Fig. 1F ). An anecdotal clinical report suggests that ipilimumab plus radiation cooperates to limit melanoma growth (60) . Further studies confirmed these results in a small subset of melanoma patients treated with ipilimumab and radiation (61) . Of note, resistance was commonly seen and explained by PD-L1 upregulation on the melanoma cells, causing T-cell exhaustion, and highlighting the need for a triple combination therapy. Another area for exploration is the potential synergistic effects of B7-H3 blockade and radiotherapy and its underlying mechanisms for future development of novel cancer immunotherapies (Fig. 1F) .
Concluding Remarks
B7-H3 has both immunologic and nonimmunologic functions. Largely overexpressed in human tumor tissues, B7-H3 positively correlates with cancer severity and poor outcome. Compared with other immune checkpoints, the B7-H3 pathway not only regulates innate and adaptive immunity but also promotes cancer cell aggressiveness through various nonimmunologic functions. Therefore, B7-H3 seems to be a unique and interesting target for future cancer immunotherapies. One of the most promising therapeutic strategies may be the use of blocking mAbs against the B7-H3 pathway. Rather than administered alone, blocking mAbs are more likely to achieve synergistic antitumor effects if they are combined with a chemotherapeutic regimen or other checkpoint inhibitors. In parallel, finding its receptor(s) and better elucidating the involvement of the B7-H3 pathway in immune responses and cancer development is crucial, as this knowledge would help with the design of more effective therapeutic agents, with the ultimate goal of complete and durable treatment of human cancers.
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